Trial Profile
PHASE II TRIAL OF R115777 IN PATIENTS WITH METASTATIC MALIGNANT MELANOMA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 19 Dec 2012 Primary endpoints amended as reported by ClinicalTrials.gov record.
- 24 Mar 2010 Actual end date (1 Jan 2010) added as reported by ClinicalTrials.gov record.
- 24 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.